(Q43717824)

26 November 2017

title

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy (English)

1 reference

26 November 2017

1 reference

8

1 reference

26 November 2017

7

Mella O

1 reference

26 November 2017

1

Lønning PE

1 reference

26 November 2017

Taylor PD

2

1 reference

26 November 2017

Anker G

3

1 reference

26 November 2017

Iddon J

4

1 reference

26 November 2017

Wie L

5

1 reference

26 November 2017

Jørgensen LM

6

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Breast Cancer Research and Treatment

26 November 2017

published in

1 reference

26 November 2017

volume

67

1 reference

26 November 2017

issue

2

1 reference

26 November 2017

page(s)

111-116

1 reference

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Diethylstilbestrol: Recommended Dosages for Different Categories of Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Assessment of response to therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Response to third-line endocrine treatment for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Breast cancer: Chemotherapy in the treatment of advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

7 January 2021

Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

7 January 2021

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

7 January 2021

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

7 January 2021

Influence of Synthetic Oestrogens on Advanced Malignant Disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

7 January 2021

Massive estrogen administration in premenopausal women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

7 January 2021

Synthetic oestrogens in mammary cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

7 January 2021

Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010619225209

7 January 2021

Identifiers

DOI

10.1023/A:1010619225209

1 reference

Dimensions Publication ID

26 November 2017

1011725288

0 references

Fatcat ID

release_ffbdb6ovorc7bdqitgodnxjgbe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ffbdb6ovorc7bdqitgodnxjgbe

24 November 2022

mapped directly with Wikidata item

1 reference